.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,350,753

« Back to Dashboard

Details for Patent: 6,350,753

Title: 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
Abstract:Nucleoside analogues containing a 1,3-dioxolane structure are suitable antiviral agents, particulary for the treatment of the HIV infections in mammals, especially humans. Examples of the nucleoside analogues include: cis-2-acetoxymethyl-4-(thymin-1'-yl)-1,3,-dioxolane, cis-2-hydroxymethyl-4-(thymin-1'-yl)-1,3-dioxolane, cis-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane, and cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane. These compounds can be in the form of their racemates or their separate enantiomers.
Inventor(s): Belleau; Bernard (late of Westmount, CA), Dixit; Dilip M. (Roxboro, CA), Nguyen-Ba; Paul (La Prairie, CA)
Assignee: Biochem Pharma Inc. (Quebec, CA)
Filing Date:Sep 30, 1998
Application Number:09/163,374
Claims:1. A compound selected from the group consisting of:

cis-2-acetoxymethyl-4-(thymin-1'-yl)-1,3,-dioxolane;

cis-2-hydroxymethyl-4-(thymin-1'-yl)-1,3-dioxolane;

cis-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane; and

cis-2-hydroxymethyl-4-(cytosin-1'yl)-1,3-dioxolane.

2. A compound according to claim 1, wherein said compound is in the form of a single optical isomer or a mixture of optical isomers.

3. A compound according to claim 1, wherein said compound is

cis-2-acetoxymethyl-4-(thymin-1'-yl)-1,3-dioxolane.

4. A compound according to claim 1, wherein said compound is:

cis-2-hydroxymethyl-4-(thymin-1'-yl)-1,3-dioxolane.

5. A compound according to claim 1, wherein said compound is

cis-2-benzoyloxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane.

6. A compound according to claim 1, wherein said compound is

cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane.

7. A compound according to claim 2, wherein said compound is

cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane.

8. A compound according to claim 7, wherein said compound is in the form of the racemic mixture.

9. A compound according to claim 7, wherein said compound is in the form of a single optical isomer.

10. A compound according to claim 6, wherein said compound is:

(d)-cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane.

11. A compound according to claim 6, wherein said compound is

(l)-cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3dioxolane.

12. A compound according to claim 2, wherein said compound is

cis-2-hydroxymethyl-4-(thymin-1'-yl)-1,3-dioxolane.

13. A compound according to claim 12, wherein said compound is in the form of the racemic mixture.

14. A compound according to claim 12, wherein said compound is in the form of a single optical isomer.

15. A compound according to claim 14, wherein said compound is

(d)-cis-2-hydroxymethyl-4-(thymin-1'-yl)-1,3-dioxolane.

16. A compound according to claim 14, wherein said compound is

(l)-cis-2-hydroxymethyl-4-(thymin-1-yl)-1,3-dioxolane.

17. A method for the treatment of an HIV infection, in a mammal, comprising administering an effective amount of a compound according to claim 9 to a mammal in need of such treatment.

18. A method for the treatment of an HIV infection, in a mammal, comprising administering an effective amount of a compound according to claim 10 to a mammal in need of such treatment.

19. A method for the treatment of an HIV infection, in a mammal, comprising C administering an effective amount of a compound according to claim 10 to a mammal in need of such treatment.

20. A method for the treatment of an HIV infection, in a mammal, comprising administering an effective amount of a compound according to claim 11 to a mammal in need of such treatment.

21. A method according to claim 17, wherein said mammal is a human.

22. A method according to claim 10, wherein said mammal is a human.

23. A method according to claim 19, wherein said mammal is a human.

24. A method according to claim 20, wherein said mammal is a human.

25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1.

26. A composition according to claim 25, wherein the amount of said compound is 10-1500 mg.

27. A pharmaceutical composition according to claim 26, wherein said compound is

cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane.

28. A pharmaceutical composition according to claim 27, wherein said compound is:

(d)-cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-dioxolane.

29. A pharmaceutical composition according to claim 27, wherein said compound is

(l)-cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3 dioxolane.

30. A pharmaceutical composition of claim 26, wherein the amount of said compound is 20-1000 mg.

31. A pharmaceutical composition of claim 27, wherein the amount of said compound is 20-1000 mg.

32. A pharmaceutical composition of claim 28, wherein the amount of said compound is 20-1000 mg.

33. A pharmaceutical composition of claim 28, wherein the amount of said compound is 20-1000 mg.

34. A pharmaceutical composition of claim 30, wherein the amount of the compound is 50-700 mg.

35. A pharmaceutical composition of claim 31, wherein the amount of the compound is 50-700 mg.

36. A pharmaceutical composition of claim 32, wherein the amount of the compound is 50-700 mg.

37. A pharmaceutical composition of claim 33, wherein the amount of the compound is 50-700 mg.

38. A compound selected from the group consisting of:

cis-2-benzoyloxymethyl-4-(cytosin-1'-yl),-1,3 dioxolane;

cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3 dioxolane;

and pharmaceutically acceptable salts, pharmaceutically acceptable esters, and pharmaceutically acceptable salts of esters thereof.

39. A compound according to claim 38, wherein said compound is cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3 dioxolane or a pharmaceutically acceptable salt, pharmaceutically acceptable ester, or pharmaceutically acceptable salt of an ester thereof, in the form of a racemic mixture or a single optical isomer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc